Jubilant Biosys Expanded capabilities of Facilities for Discovery Chemistry and In-Vitro ADME Service

Jubilant Biosys Limited announced an expansion of its facilities to support its discovery chemistry and in-vitro ADME Service offerings.

Jubilant Biosys provides services for Turning Point Therapeutics Inc. for multiple small molecule oncology research programs. Turning Point is a precision oncology company developing next-generation therapies that target genetic drivers of cancer.

Services for Turning Point Therapeutics Inc. will be conducted out of Jubilant Biosys Limited's newly built state-of-the-art Chemistry Innovation Research Center (CIRC) in Greater Noida, India. It's Chemistry Innovation Research Center has an initial capacity of 500 FTEs enabling higher operational performance for discovery chemistry services and also rapid turn-around of in-vitro ADME data for client projects.

Commenting on this expansion, Giuliano Perfetti, Chief Executive Officer, Jubilant Biosys Limited said, "We are delighted to unveil our newly built Chemistry Innovation Research Center, Greater Noida for Turning Point's and our other clients' project needs and we are looking forward to accelerating their programs through this site."

"We are excited to continue our relationship with Jubilant Biosys Limited as they start using their CIRC. They continue to provide skilled contract services for challenging synthetic chemistry projects while realizing the importance of short cycle times to deliver and provide critical in-vitro ADME data for our growing portfolio," said Siegfried Reich, Ph.D., chief scientific officer, Turning Point Therapeutics.